8-K/A

FORM 8-K AMENDMENT NO. 1

Company: CytomX Therapeutics, Inc.
Filed: June 21, 2019
Period of Report: December 19, 2018
Accession Number: 0001193125-19-178811

View Document ↗ View on SEC.gov ↗